Table 5. Top 20 significantly enriched pathways as determined by Gene Ontology (GO) enrichment analysis in dithranol-treated lesional skin at end of treatment compared to baseline from 15 patients with psoriasis.
(GO was done using Cytoscape software; Bindea et al., 2009; Shannon et al., 2003 a.o. = among others).
| GOID | GO term | P-Value | % Associated Genes | Associated genes found |
|---|---|---|---|---|
| GO:0006954 | Inflammatory response | 17.0E-18 | 6.93 | IL17A, IL1B, IL20, IL22, IL36A, IL36G, IL36RN, a.o. |
| GO:0006952 | Defense response | 52.0E-18 | 4.60 | CXCL8, CXCL9, DEFB103A, DEFB4A, IFNG, IL17A, IL1B, IL20, IL22, IL36A, IL36G, IL36RN, IL4R, IRAK2, IRF1, KRT16, a.o. |
| GO:0051707 | Response to other organism | 56.0E-18 | 6.02 | CCL2, CCL20, CCL22, CD24, CD80, COTL1, CXCL13, CXCL16, CXCL8, CXCL9, DDX21, DEFB103A, DEFB4A, a.o. |
| GO:0050663 | Cytokine secretion | 480.0E-18 | 13.78 | IFNG, IL17A, IL1B, IL26, IL36RN, IL4R, LYN, MMP12, NOS2, PAEP, PANX1, PNP, S100A12, S100A8, S100A9, a.o. |
| GO:0001816 | Cytokine production | 680.0E-18 | 6.76 | IDO1, IFNG, IL17A, IL1B, IL26, IL36A, IL36RN, IL4R, IRF1, LTF, LYN, MB21D1, MMP12, NOS2, a.o. |
| GO:0012501 | Programmed cell death | 1.0E-15 | 4.05 | CASP5, CASP7, CCL2, CCL21, CD24, CD274, CD38, IFNG, IL17A, IL1B, IRF1, IVL, KLK13, KRT16, KRT17, KRT31, KRT6A, KRT6C, KRT73, KRT74, KRT77, a.o. |
| GO:0051240 | Positive regulation of multicellular organismal process | 1.5E-15 | 4.57 | CXCL17, CXCL8, FBN2, FERMT1, GBP5, GPR68, HPSE, HRH2, IDO1, IFNG, IL17A, IL1B, IL20, IL26, IL36A, S100A8, S100A9, SERPINB3, SERPINB7, a.o. |
| GO:0001817 | Regulation of cytokine production | 2.0E-15 | 7.04 | CCL2, CCL20, CD24, CD274, CD80, CD83, CXCL17, IFNG, IL17A, IL1B, IL26, IL36A, IL36RN, IL4R, IRF1, TNFRSF9, WNT5A, a.o. |
| GO:0002237 | Response to molecule of bacterial origin | 15.0E-15 | 9.22 | S100A8, S100A9, SELE, SOD2, TIMP4, TNFRSF9, TNIP3, WNT5A, ZC3H12A, a.o. |
| GO:0070268 | Cornification | 100.0E-15 | 17.70 | DSC2, DSG3, IVL, KLK13, KRT16, KRT17, KRT31, KRT6A, KRT6C, KRT73, KRT74, KRT77, PI3, SPRR2A, SPRR2B, SPRR2D, a.o. |
| GO:0043588 | Skin development | 190.0E-15 | 8.17 | IL20, IVL, KLK13, KRT16, KRT17, KRT31, KRT6A, KRT6C, KRT73, KRT74, KRT77, LCE3A, LCE3C, LCE3E, a.o. |
| GO:0008544 | Epidermis development | 220.0E-15 | 7.63 | DSC2, DSG3, EPHA2, FERMT1, FOXE1, FURIN, HPSE, IL20, IVL, KLK13, KRT16, KRT17, KRT31, KRT6A, KRT6C, KRT73, KRT74, KRT77, a.o. |
| GO:0009617 | Response to bacterium | 240.0E-15 | 6.63 | CCL2, CCL20, CD24, CD80, CXCL13, CXCL16, CXCL8, CXCL9, DEFB103A, DEFB4A, S100A12, S100A8, S100A9, TREM1, a.o. |
| GO:0001819 | Positive regulation of cytokine production | 1.4E-12 | 7.89 | CCL2, CCL20, CD274, CD80, CD83, CXCL17, FERMT1, GBP5, HPSE, IDO1, IFNG, IL17A, IL1B, IL26, IL36A, a.o. |
| GO:0050707 | Regulation of cytokine secretion | 2.4E-12 | 13.10 | AIM2, CASP5, CD274, FERMT1, GBP1, IFNG, IL17A, IL1B, IL26, IL36RN, IL4R, LYN, MMP12, PAEP, PANX1, a.o. |
| GO:0005125 | Cytokine activity | 4.4E-12 | 10.64 | CCL20, CCL21, CCL22, CCL4L2, CXCL13, CXCL16, CXCL8, CXCL9, FAM3D, IFNG, IL17A, IL1B, IL20, IL22, IL26, a.o. |
| GO:0031424 | Keratinization | 21.0E-12 | 10.48 | IVL, KLK13, KRT16, KRT17, KRT31, KRT6A, KRT6C, KRT73, KRT74, KRT77, LCE3A, LCE3C, LCE3E, PI3, SPRR2A, SPRR2B, a.o. |
| GO:0002790 | Peptide secretion | 97.0E-12 | 6.25 | CD274, CD38, DOC2B, FAM3D, FERMT1, GBP1, GBP5, GLUL, GPR68, IFNG, IL17A, IL1B, IL26, IL36RN, IL4R, LYN, MMP12, NOS2, TREM1, WNT5A, a.o. |
| GO:0032940 | Secretion by cell | 140.0E-12 | 4.04 | AIM2, AMPD3, CASP5, IL36RN, IL4R, LCN2, LRG1, LTF, LYN, MMP12, NOS2, NR1D1, NR4A3, OLR1, PAEP, PANX1, PLA2G3, a.o. |
| GO:0009913 | Epidermal cell differentiation | 190.0E-12 | 7.91 | DSC2, DSG3, EPHA2, FURIN, IL20, IVL, KLK13, KRT16, KRT17, KRT31, KRT6A, KRT6C, KRT73, LCE3E, PI3, SLITRK6, SPRR2A, SPRR2B, SPRR2D, SPRR2E, a.o. |